RLMDRelmada Therapeutics, Inc.Signing up patients
A Study to Evaluate the Safety and Efficacy of NDV-01 in Participants With NMIBC
Non Muscle Invasive Bladder Cancer
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 70 (planned)
- Started
- Aug 1, 2024
- Main results expected
- Nov 2027
- Fully finished
- Dec 2027
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Number of Patients with Complete Response (CR) in High-Grade NMIBC
Measured over: 48 weeks
Frequency and severity of Adverse Events (AEs), including Serious Adverse Events (SAEs) and Treatment-emergent AEs (TEAEs) occurring at any time during the study Serious Adverse Events (SAEs) Treatment-Emergent Adverse Events (TEAEs)
Measured over: 48 weeks
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT06663137 · record last updated 2026-09-02 · checked 2026-11-09 15:47 UTC